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Abstract
Induction of heparin-binding epidermal growth factor-
like growth factor (HB-EGF) mRNA in mouse skin
organ culture was blocked by two pan-ErbB receptor
tyrosine kinase (RTK) inhibitors but not by genetic
ablation of ErbB1, suggesting involvement of multiple
ErbB species in skin physiology. Human skin, cultured
normal keratinocytes, and A431 skin carcinoma cells
expressed ErbB1, ErbB2, and ErbB3, but not ErbB4.
Skin and A431 cells expressed more ErbB3 than did
keratinocytes. Despite strong expression of ErbB2 and
ErbB3, heregulin was inactive in stimulating tyrosine
phosphorylation in A431 cells. In contrast, it was highly
active in MDA-MB-453 breast carcinoma cells. ErbB2
displayed punctate cytoplasmic staining in A431 and
keratinocytes, compared to strong cell surface staining
in MDA-MB-453. In skin, ErbB2 was cytoplasmic in
basal keratinocytes, assuming a cell surface pattern in
the upper suprabasal layers. In contrast, ErbB1 retained
a cell surface distribution in all epidermal layers.
Keratinocyte proliferation in culture was found to be
ErbB1-RTK–dependent, using a selective inhibitor.
These results suggest that in skin keratinocytes, ErbB2
transduces ligand-dependent differentiation signals,
whereas ErbB1 transduces ligand-dependent prolifer-
ation/survival signals. Intracellular sequestration of
ErbB2 may contribute to the malignant phenotype of
A431 cells, by allowing them to respond to ErbB1-
dependent growth /survival signals, while evading
ErbB2-dependent differentiation signals. Neoplasia
(2001) 3, 339–350.
Keywords: ErbB receptors, skin organ culture, keratinocytes, heparin - binding EGF - like
growth factor, receptor tyrosine kinase.
Introduction
The mammalian c-erbB family is comprised of four closely
related transmembrane proteins. ErbB1, ErbB2, and
ErbB4 possess receptor tyrosine kinase (RTK) activity,
and ErbB1, ErbB3, and ErbB4 bind multiple ligands of the
epidermal growth factor (EGF) family [1,2]. These ligands
can be classified based on their receptor affinities: EGF,
transforming growth factor - (TGF- ), amphiregulin
(AR), and vaccinia growth factor preferentially bind to
ErbB1, and epiregulin, betacellulin, and heparin-binding
EGF- like growth factor (HB-EGF) bind to ErbB4 in
addition to ErbB1. Finally, the heregulins (also known as
neuregulins) bind to ErbB3 and/or ErbB4, but not to
ErbB1 [3]. Ligand binding to the extracellular domain of
ErbB receptors is believed to cause receptor homo- and
heteroassociations, followed by trans -phosphorylation of
tyrosine residues in the activation loop of the kinase
domain. Tyrosine phosphorylation is thought to allow
access of Mg-ATP to the catalytic site, overcoming
autoinhibition of the kinase [4]. Other tyrosine phosphor-
ylation events, also executed in trans, lead to the
recruitment of multiple proteins bearing phosphotyrosine
binding domains [5]. Signal diversification results from
differential action of different ErbB ligands through a given
receptor [6 ], and from differential utilization of downstream
pathways by different ErbB receptor combinations [7].
Many of these combinations preferentially involve ErbB2, a
receptor for which no direct ligand has been identified.
Instead, ErbB2 is activated by heterodimerization and/or
multimerization with other ErbB receptors [8–10]. Interest-
ingly, ErbB2–ErbB3 heterodimers constitute a potent
mitogenic combination [11], despite the fact that ErbB2
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has no known ligand and the RTK activity of ErbB3 is
severely limited [12].
The physiological significance of ErbB receptors has been
established by studies of mice lacking various components
of the ErbB network (reviewed in [1 ] ). These studies
indicate that ErbB1 is more important for normal develop-
ment of the skin, lungs, mammary glands, and gastro-
intestinal tract, while ErbB2, ErbB3, and ErbB4 are more
important for the development of the heart and central
nervous system. Moreover, deregulated ErbB signaling has
been implicated in various malignancies, including tumors of
the breast, lung, ovary, and brain [13].
ErbB receptors play a prominent role in the epidermis,
which is also capable of producing several ErbB1-
selective ligands including TGF-, AR, and HB-EGF
[14]. Addition of EGF or TGF- to skin wounds also
significantly accelerates skin wound healing [15,16]. We
have previously shown that the heparin-binding EGF- like
growth factors AR and HB-EGF are rapidly and selec-
tively induced in human skin organ culture, an ex vivo
model system that faithfully recapitulates several early
events in wound healing [17]. Overexpression of multiple
ErbB ligands is also observed in psoriasis [18,19], a skin
disease characterized by marked keratinocyte hyperplasia
in the context of immunologically mediated skin inflam-
mation [20]. Forced overexpression of AR in the
epidermis of transgenic mice results in a markedly
psoriasiform phenotype, including a prominent arthritis
[21]. Substantial evidence also implicates ErbB signaling
as an important factor in the pathogenesis of non-
melanoma skin cancer [22,23]. Therefore, a thorough
understanding of ErbB signaling in the skin is important
for improving our understanding of normal and abnormal
skin physiology.
Thus far, most studies of ErbB signaling in skin have
focused on the ‘‘traditional’’ EGF receptor, ErbB1. How-
ever, the fact that epidermal development proceeds in
ErbB1 knockout mice [24–26] suggests that members of
the ErbB family other than ErbB1 may also be involved in
skin development and physiology. Indeed, ErbB2 and
ErbB3 immunoreactivity has been reported in normal
human skin [27–29], and in mouse skin and cultured
murine keratinocytes [30,31]. Recently, the immortalized
human keratinocyte cell line HaCaT has been shown to
express ErbB2 and ErbB3 in addition to ErbB1 [32].
However, none of the prior human in vivo studies provided
biochemical evidence for expression of the various ErbBs
in skin, nor did they address whether the non-ErbB1
receptors identified were functional.
The objectives of this study were to define the expression
of ErbB species in human skin by biochemical means, and to
determine whether members of the ErbB family other than
ErbB1 are required for various aspects of skin physiology.
Our findings demonstrate expression and function of multiple
ErbBs in human skin, and suggest that proliferating normal
keratinocytes and malignant A431 cells maintain a state of
ErbB1 dominance, at least in part, by restricting cell surface
expression of ErbB2.
Materials and Methods
Reagents
Human recombinant EGFwas purchased from Sigma (St.
Louis, MO) or from Becton Dickinson/Collaborative Bio-
medical Products (Franklin Lakes, NJ). Human recombinant
heregulin (heregulin -1176–246) was from R&D Systems
(Minneapolis, MN). Monoclonal antibodies directed against
ErbB1, ErbB2, ErbB3, and ErbB4 were from Labvision
(Fremont, CA), Transduction Laboratories (Franklin Lakes,
NJ) and Santa Cruz Biotechnology (Santa Cruz, CA) (Table
1). The mouse monoclonal antiphosphotyrosine antibody
4G10 and horseradish peroxidase–conjugated goat anti-
mouse IgG were from Upstate Biotechnology (Lake Placid,
NY). Complete protease inhibitor tablets were from Boeh-
ringer Mannheim Biochemicals ( Indianapolis, IN). All other
biochemicals were purchased from Sigma (St. Louis, MO).
Organ Culture
After sacrifice by CO2 inhalation, skin from adult wild-
type C57BL6 mice (Jackson Laboratories, Bar Harbor, ME)
was dissected down to the level of the panniculus carnosus,
cut into 6 1 cm2 pieces, then incubated at 378C in basal
MCDB153 medium without growth factors just as previously
described for human skin [17]. Organ cultures were
maintained for various times (0h - 24h) in the presence or
absence of various concentrations of the ErbB tyrosine
kinase inhibitors PD153035 and PD158780. The same
procedure was followed for two strains of ErbB (+/+), (+ / - ),
or ( - / - ) mice, except that the mice were less than 1 month
old at the time of sacrifice. One strain was engineered to
lack exon 2, which encodes an amino-terminal segment of
ErbB1 [24]. The second strain was engineered to lack exon
1, which encodes the promoter region and 5’-untranslated
region of ErbB1 mRNA [25]. Skin samples were processed
for RNA isolation and analyzed by northern blotting as
described below.
RNA Isolation and Northern Blotting
Total RNA was isolated by homogenization of full -
thickness mouse skin in RNAzol (Tel -Test, Friendswood,
TX) followed by cesium chloride gradient centrifugation as
previously described [34]. Ten to thirty micrograms of RNA
was separated on 1% formaldehyde agarose gels, trans-
ferred to derivitized nylon membranes (Zeta-Probe, BioRad,
Richmond CA), and hybridized against 32P- labeled HB-
EGF cDNA inserts as previously described [17]. As a control
for RNA loading and intactness, the blots were stripped and
rehybridized against 36B4, which encodes the human acidic
ribosomal phosphoprotein PO [35]. Hybridization signals
were quantitated by densitometer (Molecular Dynamics,
Sunnyvale, CA), normalized against 36B4, and expressed
either as fold changes relative to nonorgan-cultured skin or
as percentages of untreated controls.
Cell Culture
A431 human epidermoid carcinoma cells [36] and MDA-
MB-453, MDA-MB-468, and MCF-7 human breast carci-
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noma cells [37,38] were obtained from the American Type
Culture Collection (Manassas, VA) and grown in DMEM
(A431, MCF-7) or DMEM/F12 (1:1) (MDA-MB-453,
MDA-MB-468), containing 10% fetal bovine serum and
antibiotics. Normal human keratinocyte (NHK) cultures were
established from sun-protected adult human skin as
described [39] in serum-free medium optimized for high-
density keratinocyte growth (Medium 154; Cascade Bio-
logics, Portland, OR). NHKs were used for experiments in
the second or third passage. All cells were plated at 5000
cells /cm2. For cell growth experiments, NHKs were allowed
to attach overnight, after which two dishes were harvested by
trypsinization and counted in triplicate using a hemacyto-
meter (Reichert -Jung, Buffalo, NY). The remaining cultures
were then maintained for 3 days in the presence or absence
of 20 to 2500 nM of the ErbB tyrosine kinase inhibitors
PD153035, PD158780, or PD166547, followed by trypsini-
zation and counting. Standard deviations for counting were
<20% of the mean. Duplicate plates were harvested for each
data point; average cell counts obtained for duplicate
cultures differed by less than 20%. IC50 values were
determined from curves generated by linear interpolation of
the average cell counts for duplicate cultures after subtract-
ing the average cell count obtained from replicate dishes
after overnight cell attachment.
Cell and Tissue Lysis and Western Blotting
All procedures involving human volunteers were
approved by the University of Michigan Medical School
Institutional Review Board. After obtaining informed con-
sent, human skin keratomes were harvested from the
buttocks of healthy volunteers as previously described [33]
and 0.4 cm2 of tissue was extracted by boiling for 10 min in
0.5 ml of boiling, freshly-prepared, Laemmli sample buffer
(62.5 mM Tris-HCI pH 6.8, 2% sodium dodecyl sulfate
(SDS), 10% glycerol, 50 mM dithiothreitol) [40]. Cultured
cells were grown in 100 mm dishes until 70-80% confluent,
then lysed by scraping with a rubber policeman with 1 ml of
boiling Laemmli sample buffer. After a 5 minute spin at
12,000g to remove insoluble material, equal amounts of
lysate (as determined by OD280) were run on 4% to 20%
Tris–glycine gels (Novex, San Diego, CA) and transferred
electrophoretically to PVDF membranes according to the
manufacturer’s instructions. Western blots were decorated
by rocking in Dulbecco’s phosphate-buffered saline (PBS)
without calcium or magnesium (PBS) containing 5% nonfat
dry milk (NFDM) for 30 minutes and incubated overnight
with the various antibodies shown in Table 1 at 48C in
PBS/5% NFDM. The membranes were washed twice for
30 minutes with PBS/5% NFDM and incubated with
horseradish peroxidase–conjugated goat antimouse IgG
(0.5 g/mL; Upstate Biotechnology) in PBS/5% milk for 1
hour at room temperature. After two further 30-minute
washes in PBS/NFDM and a 5-minute wash in PBS plus
0.1% Tween-20, bound antibodies were detected by
chemiluminescence (ECL-Plus; Amersham Pharmacia,
Piscataway, NJ) according to the manufacturer’s instruc-
tions.
Tyrosine Phosphorylation Assay
NHK, A431, or MDA-MB-453 cells were grown until 40%
to 50% confluent, then incubated for 48 hours in their own
culture media without growth factors (NHK) or serum (A431,
MDA-MB-453). After growth factor deprivation, cells were
preincubated with 2 to 10,000 nM of the ErbB tyrosine kinase
inhibitors PD153035, PD158780, PD166547, or DMSO
vehicle for 2 hours, then stimulated with EGF (100 ng/mL)
or heregulin (50 ng/mL) for 10 minutes. After stimulation,
cells were harvested and processed for Western blotting as
described above, except that equal aliquots were defined as
equal proportions of the total lysate volume. Blots were
decorated with the antiphosphotyrosine mAb 4G10 at 0.5
g/ml. For determination of IC50 values for the various RTK
inhibitors, the ligand- inducible phosphotyrosine signals in
the 170 to 180 kDa range were quantitated using a
densitometer (Molecular Dynamics). Data are expressed
as a stimulation index (SI), calculated according to the
following formula:
SI ¼ 1 a cð Þ= b cð Þ½ ð Þ  100;
where a, b, and c are the densitometric intensities of the
170 to 180 kDa band obtained from inhibitor -pretreated,
ligand-stimulated cultures, vehicle-pretreated, ligand-
stimulated cultures, and unstimulated cultures, respec-
tively. IC50 values were determined by linear interpolation
of SI values.
Table 1. Anti -ErbB Antibodies Used in This Study.
Receptor Supplier Antibody Name Application Concentration
(g /mL )
Epitope Isotype
ErbB1 Transduction Laboratories Clone 13 WB 0.5 aa 996–1022 IgG1
ErbB1 Neo Markers Ab 13 IP 2 extracellular IgG2a
ErbB1 Neo Markers Ab 14 IF 0.4 extracellular IgG1 / IgG2a
ErbB1 Neo Markers Ab 15 IF 2 intracellular IgG1
ErbB2 Neo Markers Ab 2 IP / IF 2 extracellular IgG1
ErbB2 Neo Markers Ab 17 IF /WB 0.5 intracellular IgG1
ErbB3 Upstate Biotechnology 2F12 WB 1 aa 1295–1323 IgG2a
ErbB3 Neo Markers Ab 4 IP 2 extracellular IgG2a
ErbB4 Santa Cruz Biotechnology C7 WB 4 intracellular IgG2a
ErbB4 Neo Markers Ab 1 IP 2 extracellular IgG1
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Immunoprecipitations
NHKs were depleted of growth factors for 48 hours and
treated with EGF as described above. The cells were
washed with PBS then lysed in 1 mL ice-cold Buffer A per
dish (10 mM PIPES 6.8, 250 mM sucrose, 3 mM MgCl2, 150
mM KCl, 5 mM EGTA, 100 mM sodium fluoride, 5 mM
sodium orthovanadate, 10 mM sodium pyrophosphate, 10%
glycerol, 1% Triton X-100, and 1 protease inhibitor
cocktail ). The cell lysates were precleared by centrifugation
for 15 minutes at 3000g and 500 g of protein, as determined
by the Bradford assay (Bio-Rad, Hercules, CA), was rotated
overnight at 48C with one of the four anti -ErbB antibodies at
the concentrations listed in Table 1. Controls contained the
same concentration of an isotype-matched control mouse
IgG (Sigma). The immune complexes were bound to protein
A/G agarose (Santa Cruz Biotechnology) according to the
manufacturer’s instructions, washed three times with cold
PBS, then pelleted by centrifugation for 5 minutes at 3000g.
After boiling in Laemmli sample buffer for 5 minutes,
immunoprecipitates were analyzed by Western blotting as
described above.
Immunofluorescence Microscopy
NHK or A431 cells were seeded on glass coverslips at
5000 cells /cm2, grown to approximately 50% confluence in
complete M154 or DMEM/10% FCS, respectively, and
processed for immunofluorescence 24 hours after their last
feeding. Normal human skin was obtained from sun-
protected sites, snap- frozen in OCT compound, and
cryosectioned. Fixation and immunostaining were per-
formed exactly as previously described [41], using anti -
ErbB1 and anti -ErbB2 antibodies at the concentrations
given in Table 1. The secondary antibody was fluorescein
isothiocyanate (FITC)-conjugated goat antimouse IgG
(Santa Cruz Biotechnology), which was used at 15 g/
mL. The diluent was 1 PBS containing 1% BSA. Controls
included equivalent molar amounts of the isotype control
mAb and omission of primary antibody; all controls were
negative. Slides were examined under a Zeiss Axioskop
microscope equipped for fluorescence microscopy. Images
were captured digitally on a 2.2 megapixel diode array
camera (Optronics, Goleta, CA).
Results
Mouse Skin Organ Culture
Expression of HB-EGF mRNA was assessed after organ
culture of full - thickness dorsal mouse skin subjected to
organ culture for 2 or 24 hours. As shown in Figure 1,
induction of HB-EGF mRNA was detectable after 2 hours,
and quite marked after 24 hours. Furthermore, two ErbB
RTKIs active against all ErbB-RTKs (see below) markedly
inhibited induction of HB-EGF mRNA. After 24 hours of
organ culture, 1 M PD158780 and 0.2 M PD153035
inhibited HB-EGF mRNA to 22.6±6.5% and 45.7±9.1% of
the vehicle controls, respectively (mean±range, n=2).
We next performed additional organ culture experi-
ments with skin isolated from two different strains of
ErbB1 knockout mice [24,25]. Substantial induction of
HB-EGF mRNA was observed in both strains (Figure 2 ).
Figure 1. Inhibition of inducible HB -EGF mRNA expression in mouse skin
organ culture by ErbB -RTK inhibitors. Skin fragments were subjected to organ
culture in the presence or absence of 0.2 MPD153035 or 1 MPD158780 for
the times shown above the autoradiograms. Total RNA (30 g / lane ) was
subjected to Northern blotting and hybridized against HB -EGF or 36B4
probes as described in Materials and Methods section. 36B4 is shown as
control for RNA loading. Results for two different mice are shown.
Figure 2. Induction of HB -EGFmRNA is intact in skin organ cultures of ErbB1
knockout mice. Skin fragments from ErbB1 knockout (  /  ) mice and their
nontransgenic ( + / + ) littermates were placed in organ culture for various
times, as indicated on top of the figure. Total RNA (30 g / lane ) was subjected
to Northern blotting and hybridized against 32P - labeled HB-EGF and 36B4
cDNA probes as described in Materials and Methods section. 36B4 is shown
as control for RNA loading. Quantitative densitometry revealed a 9.3±3.6 - fold
induction of HB -EGF after 24 hours of organ culture in all ErbB1 (  /  )
animals combined (mean±SEM, n=5 ), compared to a 3.9± 0.7 - fold
induction in their ErbB ( + / + ) littermates (mean±SEM, n=5 ). The differ-
ences between ErbB ( + / + ) and ErbB (  /  ) animals were not statistically
significant (P= .198 by Welch’s unpaired t test assuming unequal variances
and a two - tailed hypothesis ).
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After densitometric quantitation and normalization for the
control gene 36B4, a 9.3±3.6- fold (mean±SEM, n=5)
induction was obtained after 24 hours of organ culture in
all ErbB ( / ) animals combined, as compared to a
3.9±0.7- fold induction in their ErbB ( + / + ) littermates
(mean±SEM, n=5). This difference was not statistically
significant. There was appreciable degradation of some of
the RNA samples, probably due to prolonged storage of
the tissue homogenates prior to final purification. Degra-
dation happened to be more severe in the ErbB1 ( + / + )
group (data not shown). The mean normalized fold
induction of HB-EGF mRNA in the ErbB1 ( / ) animals
was comparable to that obtained in the experiments
shown in Figure 1, in which RNA purification was carried
out immediately after skin was harvested (10.8±3.6- fold,
mean±range, n=2).
The experiments depicted in Figures 1 and 2 suggested
that the organ culture HB-EGF response was at least
partially dependent upon ErbB-RTK activity, but not
specifically dependent on the presence of ErbB1. This
implied that ErbB species other than ErbB1 must be
available to carry out the required signaling events, at
least in ErbB1 ( / ) mice. We proceeded to address
this question further in human skin because ( i ) we have a
dermatological interest in human skin problems, ( ii ) mouse
and human skin behave similarly in organ culture (see
Discussion section), and ( iii ) a comprehensive panel of
appropriate antibodies was available for humans but not
for mice.
Expression of ErbB Receptors in Human Skin, Carcinoma
Cell Lines and NHK
We detected ErbB1, ErbB2, ErbB3, and ErbB4 in ionic
detergent lysates by Western blotting, using antibodies
specifically directed against the four ErbB family members.
The sources and concentrations of antibodies used are
given in Table 1. The specificity and sensitivity of these
antibodies were assessed by analysis of A431, MDA-
MB453, MDA-MB-468, and MCF-7 cells (Figure 3 ). As
shown in Figure 3A, A431 cells expressed substantial
amounts of ErbB1, as expected given the 30- fold
amplification of the ErbB1 gene in these cells [42].
However, they also expressed substantial amounts of
ErbB2 and ErbB3, but little ErbB4. MDA-MB-453 cells
Figure 3. Presence of multiple ErbB receptors in human keratinocytes and skin. (A ) Ionic detergent lysates were prepared from normal human skin as well as NHK,
A431, MDA-MB -453, MDA-MB -468, and MCF-7 cells as described in Materials and Methods section. All cell cultures except those labeled ‘‘NHK KBM’’ and ‘‘NHK
KBM/EGF’’ were grown in complete medium and harvested at approximately 80% confluence. The cells shown in lanes ‘‘NHK KBM’’ and ‘‘NHK KBM/EGF’’ were
grown in complete medium until 40% to 50% confluent, growth factor –depleted for 48 hours, then treated with 100 ng /mL EGF or PBS vehicle for 10 minutes. Equal
amounts of protein lysate were analyzed by Western blotting. Replicate blots were decorated with ErbB1, ErbB2, ErbB3, and ErbB4 antibodies. See Table 1 for
antibody concentrations and isotypes. The band indicated by the filled triangle co -migrated with a prominent band on amido black - stained filters, and was not seen
using different anti -ErbB1 primary antibodies, or by immunoprecipitation (data not shown ). Also, this band partitioned into the insoluble fraction of the homogenate
when skin homogenates were prepared in the absence of detergents (data not shown ). Therefore, this band probably represents nonspecific cross reactivity of this
particular anti -ErbB1 antibody with keratin. Keratinocyte cultures prepared from three different donors all demonstrated comparably low expression of ErbB3 (data
not shown ). (B ) Immunoprecipitation of ErbB1, ErbB2, and ErbB3 in NHK and carcinoma cell lines. Nonionic detergent lysates of the indicated cell lines were
immunoprecipitated, then subjected to Western blotting for detection of the same ErbB species. The ErbB3 panel is a 10 -minute exposure, whereas the ErbB1 and
ErbB2 panels are 1 -minute exposures. No ErbB1 was detectable in MDA-MB-453 cells, even after 10 minutes of exposure ( not shown ). ErbB4 results are not
shown because none of the antibodies we tested immunoprecipitated ErbB4 from MDA-MB-453 cell lysates. (C ) Ligand - stimulated tyrosine phosphorylation in
NHK and carcinoma cell lines. Cells were growth factor –depleted and stimulated with ligand, followed by ionic detergent extraction and Western blotting for
phosphotyrosine. Note that the ability to be stimulated by EGF correlates with the presence of ErbB1, but that the ability to be stimulated by heregulin does not
correlate with the presence of ErbB2 and ErbB3.
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yielded very strong expression of ErbB2, and readily
detectable amounts of ErbB3 and ErbB4. The anti -ErbB1
antibody detected a faint 180 to 185 kDa band in MDA-
MB-453 cells. However, this band could not be immuno-
precipitated by a second antibody directed against a
different epitope of ErbB1 (Figure 3B ). In MDA-MB-468
cells, we detected large amounts of ErbB1, moderate
amounts of ErbB3, and low levels of ErbB2 (Figure 3A ).
Finally, MCF-7 cells expressed little or no ErbB1 or ErbB4,
but readily detectable ErbB2 and ErbB3. These results
Figure 4. Immunofluorescence microscopy of ErbB1 and ErbB2 in actively growing NHK, MDA-MB-453, and A431 cells (A ) and normal human skin (B ).
Immunofluorescence was carried out as described in Materials and Methods section, using anti -ErbB1 and ErbB2 antibodies at the concentrations indicated in Table
1. (A ) Cultured cells. Note differential compartmentalization of ErbB1 and ErbB2 in A431 cells and NHK. Similar results were observed for at least two anti -ErbB1
and anti -ErbB2 antibodies ( data not shown ). (B ) Normal human skin. Photomicrographs taken through the 40 objective are shown. Note the plasma membrane
( ‘‘chicken wire’’ ) staining pattern throughout all epidermal layers for ErbB1, whereas a discrete plasma membrane staining pattern is only observed in the uppermost
epidermal layers for ErbB2. The results shown are representative of those obtained for at least three normal individuals. Similar results were obtained with at least
two different antibodies each for ErbB1 and ErbB2 (data not shown ).
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were in good agreement with the available literature (see
Discussion section).
Having validated our assays, we proceeded to analyze
ionic detergent lysates from human skin and cultured
keratinocytes. ErbB1, ErbB2, and ErbB3 were consistently
detected byWestern blotting in normal human skin and NHK.
ErbB3 expression was substantially lower in normal kerati-
nocytes than in human skin on a protein basis; A431 cells
also expressed higher levels of ErbB3 than did NHK (Figure
3A ). Across a large number of experiments involving three
different antibodies, ErbB4 immunoreactivity was very low to
undetectable in keratinocytes and skin (Figure 3A, data not
shown).
We next compared the ligand specificity of total cell
tyrosine phosphorylation after a 10-minute stimulation with
EGF or heregulin. As shown in Figure 3C , A431 cells,
MDA-MB-468 cells, and NHK displayed robust tyrosine
phosphorylation in response to EGF, but not in response to
heregulin. Conversely, MDA-MB-453 cells displayed
robust tyrosine phosphorylation in response to heregulin,
but not in response to EGF. For the most part, these
patterns of ligand- induced tyrosine phosphorylation corre-
lated well with the receptor profiles shown in Figure
3A and B, given the established ligand specificities of each
receptor [1,2 ]. However, the failure of A431 and NHK cells
to respond to heregulin was puzzling, given that A431 cells
expressed large amounts of ErbB2 and ErbB3, and NHK
expressed substantial amounts of ErbB2 and at least some
ErbB3.
Subcellular Localization of ErbB1 and ErbB2
One possible explanation for the failure of A431 cells and
NHK to respond to heregulin would be intracellular compart-
mentalization of ErbB2. Indeed, immunofluorescence micro-
scopy revealed markedly different patterns of intracellular
distribution for ErbB1 and ErbB2 in proliferating A431 cells
and NHK, compared to MDA-MB-453 cells. In A431 and
NHK, ErbB1 displayed a well -defined cell surface pattern,
together will low levels of punctate intracytoplasmic staining.
In contrast, ErbB2 displayed only the punctate cytoplasmic
pattern, with no evidence of membrane staining (Figure 4A ).
Similar patterns were observed with two other anti -ErbB2
antibodies (data not shown). In MDA-MB-453 cells, ErbB1
was not detectable, consistent with the Western blotting
results. However, unlike A431 and NHK, MDA-MB-453 cells
showed a strong pattern of cell surface ErbB2 staining
(Figure 4A ). Cells in dense keratinocyte cultures often
became large and flattened, and express makers of
epidermal differentiation. These large, flattened cells often
displayed a cell surface staining pattern for ErbB2, whereas
A431 cells remained rhomboidal in shape in dense cultures
and did not display cell surface expression of ErbB2 (data
not shown).
Next, cryostat sections of normal human skin were
immunostained for ErbB1 and ErbB2 (Figure 4B, left
panel ). The ErbB1 antibody revealed a strong ‘‘chicken
wire’’ staining pattern in all epidermal layers, consistent
with cell membrane staining. Higher power views through
the 100 oil immersion objective (not shown) reveal
that this ‘‘chicken wire’’ pattern is comprised of linear
plasma membrane staining together with punctate stain-
ing in the cortical cytoplasm just beneath the plasma
membrane. Scattered punctate staining was also seen at
low levels throughout the cytoplasm. In contrast, ErbB2
staining was diffusely cytoplasmic and punctate in the
lower epidermal layers, transitioning to an increasingly
cortical submembranous location in the upper suprabasal
layers, and finally to a sharp ‘‘chicken wire’’ pattern in
the stratum granulosum, the uppermost viable keratino-
cyte layers just below the stratum corneum (Figure 4B,
right panel ).
Validation of ErbB-RTK Inhibitors
We next utilized ErbB-RTK inhibitors of varying
specificity to explore the functional contribution of different
ErbB receptors to keratinocyte growth in culture. Three
inhibitors were selected for study. Two of them,
PD158780 and PD153035, were previously shown to
have similar inhibitory potencies against ErbB1 versus
non-ErbB1-RTKs, whereas a third, PD166547 ( ‘‘com-
pound 5k’’ in Ref. [43] ), was approximately 40- fold more
potent against ErbB1-RTK than against non-ErbB1-RTKs
(Table 2) [43–45]. Because the specificity of inhibitors is
a critical issue, we repeated these dose–response
experiments under low-calcium, serum-free conditions
known to be optimal for EGF-stimulated proliferation
and gene responses in NHK [46,47]. PD158780 and
PD153035 markedly and potently inhibited ligand-stimu-
lated tyrosine phosphorylation under these conditions in
EGF-stimulated A431 cells and in heregulin-stimulated
Table 2. Relative Potencies of ErbB -RTK Inhibitors.
Compound IC50 Values for Inhibition of Ligand - Induced Tyrosine Phosphorylation IC50 Values for Inhibition of NHK
EGF-Stimulated A431 Cells Heregulin -Stimulated MDA-MB -453 Cells EGF -Stimulated NHK Growth in Complete Medium
Previous
Reports* (nM)
This Report
( nM)
Previous Reports*
( nM)
This Report
( nM )
This Report
( nM)
This Report
( nM )
PD153035 13 <2 195 <2 <2 68
PD158780 14 <2 52 <2 <2 95
PD166547 28 8 1100 365 72 490
*Refs. [ 43–45 ].
Neoplasia . Vol. 3, No. 4, 2001
Multiple ErbB Receptors in Skin Stoll et al. 345
MDA-MB-453 cells (Table 2). In contrast, and consistent
with previous reports [43], PD166547 was clearly less
potent in heregulin-stimulated MDA-MB-453 cells than in
EGF-stimulated A431 cells, MDA-MB-468 cells, and
NHK (Figure 5, Table 2). Table 2 also demonstrates that
all of these compounds were more potent in our hands
than previously reported [43–45], possibly due to the use
of culture conditions known to be optimized for ErbB
signaling [46,47].
Effects of ErbB-RTK Inhibitors on NHK Growth
We next assessed the effects of the same three
inhibitors on NHK cell number in a 3-day growth assay.
In this assay, the growth medium contained insulin and
bovine pituitary extract in addition to EGF. Under these
conditions, all three compounds were substantially (10 to
50 times) less active as inhibitors of NHK growth than they
were as inhibitors of EGF-stimulated tyrosine phosphor-
ylation (Figure 6, Table 2, also see Discussion section).
PD153035 and PD158780 were similarly potent in their
ability to inhibit NHK growth, whereas PD166547 was five-
to seven- fold less potent in this regard (Figure 6, Table 2).
PD158780 and PD153035 were also at least four times
more potent as inhibitors of EGF-stimulated tyrosine
phosphorylation in A431 cells, compared to PD166547
(Table 2). Taken together, these results indicated that
relative to their intrinsic potencies as RTK inhibitors, all
three compounds were approximately equally efficacious
as inhibitors of NHK growth despite large differences in
their selectivity for ErbB1.
Discussion
Historically, substantial evidence has accumulated to impli-
cate ErbB1, the cardinal member of the ErbB family, in the
control of epidermal growth and differentiation. However,
much of the earlier data made use of EGF binding assays
Figure 5. Inhibition of ligand - stimulated tyrosine phosphorylation in carci-
noma cell lines and NHK by PD166547. Cells were cultured, deprived of
growth factors, preincubated for 2 hours with inhibitors or DMSO vehicle, then
stimulated for 10 minutes with heregulin or EGF as detailed in Materials and
Methods section. Western blots were decorated with the antiphosphotyrosine
antibody 4G10. Bands shown illustrate the areas of the gels used for
quantitation of tyrosine phosphorylation in Table 2. Note the lower potency of
PD166547 in MDA-MB-453 cells.
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Figure 6. Inhibition of EGF -stimulated tyrosine phosphorylation and growth
of NHK in response to the ErbB tyrosine kinase inhibitors PD158780,
PD153035, and PD166547. (A ) Tyrosine phosphorylation assay. NHK were
growth factor –depleted, pretreated with inhibitor, and stimulated with EGF for
10 minutes as described in Materials and Methods section. After Western
blotting and decoration with antiphosphotyrosine mAb 4G10, the prominent
ligand - inducible band at 170 to 180 kDa was quantitated by densitometric
scanning of autoradiograms. Stimulation indices were calculated as described
in Materials and Methods section and expressed as a percentage of the
response obtained for ligand - treated cells in the absence of inhibitor.
Negative stimulation indices indicate that tyrosine phosphorylation was
blocked to below basal levels. PD166547, open circles. PD158780, open
squares. PD153035, solid squares. Number of replicates: PD153035, n=3;
PD158780, n=5, PD166547, n=3. Error bars represent SEM. (B ) Growth
assay. NHKs were grown in complete medium in the presence of the various
inhibitors or diluent for 72 hours without change of medium, then harvested by
trypsinization and counted as described in Materials and Methods section. The
data are expressed as percent of untreated controls. Error bars indicate
mean±SEM. The number of replicates: PD153035, n=4; PD158780, n=6;
PD166547, n=3.
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that would not detect ErbB1 specifically [48]. The discovery
of multiple additional members of the ErbB family [1,2]
raises the question of whether ErbB1 is the sole mediator of
these processes in the skin. We have addressed this
question via a combination of approaches, including knock-
out mice, immunoblotting, pharmacologic inhibitors, and
immunolocalization experiments.
As shown in Figure 1, both PD153035 and PD158780
markedly inhibited the HB-EGF mRNA response in organ
cultures prepared from wild type mice. Both compounds
inhibited the mouse skin response with the same potency
they displayed in human skin organ culture (Ref. [17] and
data not shown). This suggests that ErbB signaling plays a
similar role in the skin organ culture response in man and
mouse. However, two strains of ErbB1 ( / ) animals
demonstrated very similar induction of HB-EGF mRNA
compared to their wild - type littermates (Figure 2 ) or to other
wild- type animals (Figure 1 ). This would not be expected if
ErbB1 were the only relevant ErbB species involved in the
skin organ culture response. These results cannot be
explained by nonspecificity of the inhibitors, as we utilized
PD153035 and PD158780 at 0.2 to 1 M, concentrations
well below their thresholds of activity against non-ErbB
RTKs (50 M) [43–45]. Alternatively, it could be argued
that the exon 2 knockout construct might express the
cytoplasmic domain of ErbB1 due to alternative splicing.
Indeed, a minor ErbB1- immunoreactive band has been
reported in keratinocytes from another ErbB1 exon 2
knockout strain [49]. However, the ErbB1 exon 1 knockout
we tested has been shown to be totally lacking in ErbB1
mRNA expression [25], and the only ErbB1 mRNA
expressed by the exon 2 knockout we tested contains
multiple stop codons (Z.W., unpublished data).
It could also be argued that ErbB family members other
than ErbB1 come into play only when ErbB1 is genetically
ablated. However, our own earlier studies of human skin
organ culture [17] argue against this interpretation. In those
studies, mAb 225 IgG was utilized as a reagent to block
inducible HB-EGF expression in organ culture. 225 IgG is
known to specifically inhibit ligand activation of ErbB1-RTK
in A431 cells [50]. Despite use of 225 IgG concentrations 16
times higher than required to completely inhibit ligand-
induced ErbB tyrosine phosphorylation, and >50 times
higher than that required to maximally inhibit EGF- inducible
TGF- expression [47], 225 IgG inhibition was substantially
less complete than that produced by nontoxic doses of the
pan-ErbB inhibitor PD153035 (Table 2 of this report, and
Figure 2 of [17] ). As discussed in more detail below, Figure 3
documents robust expression of ErbB1, ErbB2, and ErbB3 in
human skin. Taken together, these results strongly suggest
that multiple ErbB species participate in the human skin
organ culture HB-EGF response, even when ErbB1 is
present.
In order to identify sensitive and specific reagents for
detection of each ErbB species, we screened a total of 15
commercially available antibodies. To validate the specificity
and sensitivity of these antibodies, we tested them against a
panel of commonly used tumor cell lines. The results provide
a uniform comparison of ErbB expression in these lines for
the first time. MDA-MB-468 cells expressed large amounts
of ErbB1, moderate amounts of ErbB3, and a small amount
of ErbB2, as previously reported [51,52]. In our hands,
MCF-7 cells expressed ErbB2 and ErbB3, but no ErbB1 and
little or no ErbB4 (Figure 3 ). It has long been established that
ErbB2 and ErbB3 are expressed by MCF-7 cells [53]. While
one recent report found expression of ErbB4 in this cell type
[54], two other reports found little or no ErbB4 unless it was
ectopically expressed [55,56]. A431 cells expressed sub-
stantial amounts of ErbB1, ErbB2, and ErbB3, but very little
ErbB4 (Figure 3A ). These findings were confirmed by
immunoprecipitation using antibodies directed against differ-
ent epitopes of ErbB1, ErbB2, and ErbB3 (Figure 3B ). This
pattern is similar to previous reports [57,58] and is of interest
because earlier studies emphasized gene amplification and
overexpression of ErbB1 in A431 cells [42] without consid-
ering the other ErbB species. We found that MDA-MB-453
cells expressed large amounts of ErbB2, lesser but
substantial amounts of ErbB3 and ErbB4, and small amounts
of a 180- to 185-kDa band detected by anti -ErbB1. This
band probably represents cross reactivity against ErbB2
because it co-migrated with ErbB2 and because we could
not detect it by immunoprecipitation using a different anti -
ErbB1 antibody (Figure 3B ). This expression pattern is also
in good agreement with previous reports [45,52]. However,
we found more ErbB4 in MDA-MB-453 cells than reported
by others [52]. Substantial amounts of all four ErbB mRNAs
have been detected in MDA-MB-453 cells by RT-PCR [59].
Taken together, these results validate the specificity of the
antibodies used, and demonstrate that these frequently used
tumor cell lines display characteristic patterns of ErbB
protein expression. However, they also suggest that these
lines probably undergo stochastic or adaptive changes in
ErbB expression as they are maintained in culture.
Despite the fact that A431 cells, NHK, and MDA-MB-453
cells all expressed substantial amounts of ErbB2 and ErbB3,
very different patterns of ligand-stimulated tyrosine phos-
phorylation were observed between ErbB1-expressing
A431 cells and NHK on one hand, and ErbB1-nonexpress-
ing MDA-MB-453 cells on the other (Figure 3C ). Some of
these differences are explicable in light of current theories of
receptor activation [4], known patterns of ligand–receptor
binding and intrinsic RTK activity [1,2], and the ErbB
expression patterns shown in Figure 3. MDA-MB-453 cells
showed only a slight increase in tyrosine phosphorylation in
response to EGF, as compared to a 20- to 100- fold
induction in response to heregulin (Figure 3C ). Similar
observations have been reported recently [52]. This
response probably reflects the lack of ErbB1 in MDA-MB-
453 cells, coupled with the fact that EGF does not bind
efficiently to any of the other ErbB species [1,2 ]. In contrast,
A431 cells and NHK showed only a slight increase in protein
tyrosine phosphorylation in response to heregulin, as
compared to a 20- to 100- fold increase in response to
EGF (Figure 3C ).
This lack of heregulin responsiveness is only partially
explained by recalling the very low affinity of heregulin for
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ErbB1 [60] coupled with lack of ErbB4 (Figure 3A ). Co-
expression of ErbB2 and ErbB3 in cells that normally lack
ErbB receptors leads to robust tyrosine phosphorylation of
ErbB2 and ErbB3 [61,62]. NHK expressed only low levels of
ErbB3 (Figure 3A and B ), meaning that these cells could
only form limited amounts of ErbB2–ErbB3 heterodimers to
serve as a functional heregulin receptor. This could explain
why NHKs were unresponsive to heregulin. However, low
ErbB3 levels cannot explain why heregulin -dependent
tyrosine phosphorylation was not observed in A431 cells,
as both of these receptors are well expressed in A431
(Figure 3A ). This paradox can be explained by the
observation that ErbB2 was confined to the cytoplasm of
A431 cells (Figure 4A ), suggesting that ErbB2 and ErbB3
are unable to form a functional heregulin receptor on the
surface of A431 cells. Interestingly, a similar phenomenon
was observed in intact skin. ErbB1 retains a predominantly
peripheral plasma membrane and cortical submembranous
location throughout the epidermis, forming a ‘‘chicken wire’’
pattern (Figure 4B ). In contrast, ErbB2 assumes a diffuse
punctate distribution throughout the cytoplasm in the basal
and lower suprabasal keratinocytes that comprise the
proliferative compartment of the epidermis, but transitions
to a discrete ‘‘chicken wire’’ pattern in the highly differentiated
keratinocytes of the upper epidermal layers (Figure 4B ).
Taken together, the absence of ErbB4, the lack of cell
surface ErbB2, and the inactive nature of the ErbB3RTK lead
us to conclude that addition of EGF to rapidly proliferating
A431 cells or NHK must primarily stimulate ErbB1-RTK
activity (although later activation of intracellular ErbB2 cannot
be ruled out ). These findings support the use of A431 cells
stimulated briefly with EGF as a selective assay for ErbB1-
RTK activity. Because we and others have found no ErbB1 in
MDA-MB-453 cells, we can also justify the use of MDA-MB-
453 cells stimulated briefly with heregulin as an assay for
ErbB-RTKs other than ErbB1. Using these assays (Table 2),
we found that the RTK inhibitor PD166547 was about 45
times more potent in EGF-stimulated A431 cells than it was
in heregulin-stimulated MDA-MB-453 cells, confirming ear-
lier reports of a 40- fold ErbB1 selectivity for this compound
[43]. In contrast, PD153035 and PD158780 were of very
similar potency in the two assays and therefore represented
‘‘pan-ErbB’’ inhibitors. By comparing the potency of the three
inhibitors in EGF-stimulated A431 cells, we could obtain an
estimate of their intrinsic potencies. As shown in Table 2,
PD166547 was at least four times less potent than either
PD153035 or PD158780. PD166547 was also five to seven
times less potent as a growth inhibitor for NHK, compared to
the two pan-ErbB inhibitors (Figure 6 ). These differences in
growth- inhibitory potency approximately match the differ-
ences in intrinsic potency, despite the fact that PD166547 is
40 to 45 times more potent against ErbB1-RTK than against
the other ErbB species. Taken together, these results
strongly suggest that ErbB1-RTK plays a predominant role
in the regulation of NHK growth in culture.
NHK growth inhibition required 50 to 100 times more
RTK inhibitor than was required to inhibit ligand-stimu-
lated ErbB tyrosine phosphorylation (Table 2). Similar
observations have been made previously [44,45]. Given
the presence of the non-EGF mitogens insulin and bovine
pituitary extract in the keratinocyte growth medium, this
difference is most likely due to the contributions of non-
ErbB signaling pathways to the process of keratinocyte
growth. Indeed, we have observed that ErbB-RTKIs are
at least an order of magnitude more potent as growth
inhibitors when non-EGF mitogens are omitted from the
growth medium [70]. This phenomenon probably also
explains the lower potencies of these compounds in the
skin organ culture system (Figure 1 ), in which a variety of
signaling pathways in addition to ErbB are likely to be
active.
These results are consistent with our previous work
demonstrating that the mAb 225 IgG, which specifically
blocks the ligand- inducible activation of ErbB1-RTK [50],
is a potent inhibitor of NHK growth [47,63]. NHKs express
high levels of the ErbB1-selective, EGF- like ligands HB-
EGF, AR, and TGF- in an autocrine fashion [46,47,64].
In contrast, heregulin expression appears to be limited
relative to TGF-, AR, and HB-EGF in cultured kerati-
nocytes [65], and heregulins are not potent mitogens for
keratinocytes relative to EGF [30,66]. Moreover, heregulin
produced only a slight increase in tyrosine phosphoryla-
tion in NHK (Figure 3 ) due to low expression of ErbB3
(Figure 3 ) and/or to intracellular compartmentalization of
ErbB2 (Figure 4 ). Taken together, these findings suggest
that ligand-dependent ErbB-mediated keratinocyte prolif-
erative responses pass primarily through ErbB1, whereas
ligands of the heregulin family interacting with ErbB2 on
the cell surface of upper- layer keratinocytes may play an
important role in terminal differentiation. Recent studies
(Predd H, Underwood R, Peterson T, Cook P, and
Piepkorn M. Society for Investigative Dermatology 2001
Annual Meeting, Abstract 104) demonstrate that differ-
entiating keratinocytes in culture and in intact human skin
express heregulin in the same distribution we have
observed for ErbB2. As ErbB1 expression is maintained
throughout the epidermis (Figure 4B ), ErbB1-selective
ligands may also interact with ErbB2 in differentiated
keratinocytes. Indeed, AR, which binds exclusively to
ErbB1 [1,2 ], has been implicated in the control of what is
arguably the most highly differentiated response of
keratinocytes: maintenance of the stratum corneum per-
meability barrier [67].
This conclusion returns us to the original observations
that initiated this work: mouse skin organ cultures appear to
be highly dependent on ErbB signaling (Figure 1 ), yet
independent of ErbB1 (Figure 2 ). Early epidermal wound
healing responses are dominated by specialized and
accelerated differentiation responses, which proceed for 1
to 3 days prior to the onset of significant epidermal
proliferation in vivo [68] and in organ culture [17]. The
primary function of these early responses, during which
keratinocytes flatten and rapidly migrate to cover the wound,
is to restore epidermal barrier function as rapidly as possible.
Based on our results, we would speculate that signaling
through ErbB family members other than ErbB1 in differ-
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entiated keratinocytes of the upper epidermal layers may be
critical for these early wound healing responses, including
induction of HB-EGF.
Finally, our data suggest that intracellular sequestration of
ErbB2 may be an important mechanism by which malignant
A431 cells limit their responsiveness to heregulin. If the
interactions of ligands such as AR and heregulin with cell
surface ErbB2 lead to growth arrest and terminal differ-
entiation, as has been suggested for skin [67] and mammary
epithelial cells [69], then the ability of A431 cells to limit cell
surface expression of ErbB2 may be an important mecha-
nism by which A431 and other skin carcinomas evade
terminal differentiation signals in vivo. The intermingling of
differentiation and proliferation has long been a puzzling
feature of squamous cell carcinomas. Unraveling the
mechanisms by which A431 cells limit cell surface expres-
sion of ErbB2 may provide new avenues for differentiation
therapy of epithelial cancers, which in aggregate account for
over 90% of all human malignancies.
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